NCT02407184

Brief Summary

Understanding the microbiome's important role in human health, the investigators wish to determine how the development of the infant microbiome is impacted by delivery mode, comparing natural vaginal birth to scheduled C-sections. Investigators will look at the oral, nasal, skin, vaginal and fecal bacteria of 78 mothers and their infants from birth to age 1.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Apr 2015

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 5, 2015

Completed
27 days until next milestone

Study Start

First participant enrolled

April 1, 2015

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 2, 2015

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2018

Completed
Last Updated

January 12, 2018

Status Verified

January 1, 2018

Enrollment Period

2.8 years

First QC Date

March 5, 2015

Last Update Submit

January 10, 2018

Conditions

Keywords

MicrobiotaMicrobiome

Outcome Measures

Primary Outcomes (1)

  • Bacterial diversity of several body sites on mother and baby throughout one year post-birth as measured by the number and type of different bacteria present

    Investigators will first use Illumina to obtain sequences of the bacterial mitochondrial DNA from collected samples. QIIME, LEfSe, and other bioinformatic tools will then be used to calculate the bacterial diversity (richness, relative abundances) in each sample, as well as compare bacterial communities (beta diversity), sourcetracking to determine origin from maternal sites, random forest to classify communities, and other tools to describe the dynamics of the infant microbiome.

    Day of Birth; Days 1 and 3; Weeks 1, 2, 3 and 4; Months 2, 3, 4, 5, 6, 7, 8, 9, 10, 11; Year 1

Study Arms (3)

Scheduled C-section

NO INTERVENTION

Babies that are scheduled to be born in a hospital via standard C-section procedure.

Vaginal Delivery

NO INTERVENTION

Babies that are born via vaginal delivery, either at home, at a birthing center or hospital. Drugs may be administered during labor.

Scheduled C-section with Exposure

EXPERIMENTAL

Babies that are scheduled to be born in a hospital via standard C-section procedure, as well as are swabbed with gauze containing their mother's vaginal microbiota just after delivery. The intervention: Newborn exposure to mother vaginal microbiota.

Other: Newborn exposure to mother vaginal microbiota

Interventions

Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.

Scheduled C-section with Exposure

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy mothers, 18-40 years old with uncomplicated pregnancies delivering at term (37 weeks or later)
  • Mothers of any ethnic or social background that can speak, read, and understand English to the extent that they can consent in English OR mothers who do not speak English yet agree to come to an NYU hospital for all sampling.
  • Scheduled C-section
  • Vaginal pH ≤ 4 at the time of birth (as measured via pH paper)

You may not qualify if:

  • Mothers with pre-eclampsia or other serious chronic conditions
  • Mothers with complicated pregnancies
  • Mothers under 18 years of age or over 40 years of age
  • Babies with complications during delivery
  • Babies delivered prior to 37 weeks of gestation
  • Mothers reported positive to active primary herpes, genital warts, HIV, Group B Streptococcus, gonorrhea, chlamydia, bacterial vaginosis, yeast infection, or trichomoniasis.
  • Mothers with vaginal pH \> 4 at the time of birth (as measured via pH paper).
  • Known positive Group B Strep test results by rectal vaginal swab within five weeks of the scheduled caesarian.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

New York, New York, 10010, United States

Location

Study Officials

  • Maria Gloria Dominguez-Bello, PhD

    NYU School of Medicine

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 5, 2015

First Posted

April 2, 2015

Study Start

April 1, 2015

Primary Completion

January 1, 2018

Study Completion

January 1, 2018

Last Updated

January 12, 2018

Record last verified: 2018-01

Locations